Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

Updates arrive automatically.

  • FEMSA Announces Third Quarter 2026 Results
    PR·

    FEMSA Announces Third Quarter 2026 Results

    Fomento Económico Mexicano, S.A.B. de C.V. ("FEMSA") (NYSE:FMX, BMV:FEMSAUBD, FEMSAUB)) announced today its operational and financial results for the third quarter of 2026. Reporting Segments Update: In our continuous effort to improve our disclosure, we have updated FEMSA’s reporting segment structure to better reflect the scale, stage of development, and strategic differentiation of our various operations. This updated structure should provide investors with greater visibility into the drivers of performance across our operations. Our updated reporting segments are as follows: i) OXXO Mexico; ii) Americas & Mobility which now inclu

    $FMX
  • John Marshall Bancorp, Inc. Declares Quarterly Cash Dividend
    PR·

    John Marshall Bancorp, Inc. Declares Quarterly Cash Dividend

    John Marshall Bancorp, Inc. (NASDAQ:JMSB) (the "Company"), today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 for each share of its common stock outstanding. The dividend is payable on December 2, 2026, to shareholders of record as of the close of business on November 10, 2026. Based on the current number of shares outstanding, the aggregate payment will be approximately $1.4 million. The declaration and payment of future dividends are subject to the sole discretion of the Board of Directors and will depend on a number of factors, including general and economic conditions, the Company’s financial condition and operating results, the Company’s avail

    $JMSB
  • Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
    PR·

    Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

    PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability 29 of 30 planned U.S. sites already activated Global expansion progressing toward ~115 total sites, with CTA clearance in Canada and submissions under review in Europe and other international countries 12-week induction topline results expected Q4 2027

    $PALI
  • Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th
    PR·

    Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th

    Financial Results to Be Released Before Market OpenWhite Bear Lake, Minnesota--(Newsfile Corp. - October 28, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has updated the time of its conference call to discuss financial results for the third quarter ended September 30, 2026. The conference call will now be held at 8:00 A.M. ET on Thursday, November 5, 2026. The Company will report its third quarter financial results before the market opens on the same day. Third Quarter 2026 Financial Results Conference Call:Date: Thursday, November 5, 2026Time: 8

    $COCH
  • MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
    PR·

    MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026

    MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation at the Precision Liver Symposium 2026, taking place November 4, 2026, in Denver, Colorado. Precision Liver Symposium Presentation DetailsTitle: DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in M

    $MTVA
  • Quantum Computing Inc. Announces Participation in Upcoming November Investor Conferences
    PR·

    Quantum Computing Inc. Announces Participation in Upcoming November Investor Conferences

    Quantum Computing Inc. ("QCi" or the "Company") (NASDAQ:QUBT), a vertically integrated quantum company pioneering photonics and semiconductor manufacturing, today announced that management will be participating in the following investor conferences: Cantor Convergence: 4th Annual Crypto, FinTech, AI & Energy Infrastructure Conference on Wednesday, November 11 in MiamiBMO's inaugural Technology and Innovation Leaders Conference on Thursday, November 12 in New York CityPlease contact your sales representative to register for any of the above conferences and to schedule a meeting with Q

    $QUBT
  • FLAGSTAR BANK, N.A. DECLARES QUARTERLY CASH DIVIDENDS ON ITS COMMON STOCK AND PREFERRED STOCKS
    PR·

    FLAGSTAR BANK, N.A. DECLARES QUARTERLY CASH DIVIDENDS ON ITS COMMON STOCK AND PREFERRED STOCKS

    Flagstar Bank, N.A. (NYSE:FLG) (the "Bank") today announced that its Board of Directors declared a quarterly cash dividend of $0.01 per share on the Bank's common stock. The dividend is payable on December 17, 2026, to common stockholders of record as of December 7, 2026. In addition, the Board of Directors declared quarterly cash dividends on three series of its preferred stock. A quarterly cash dividend on its Fixed-to-Floating Rate Noncumulative Perpetual Preferred Stock, Series A (NYSE: FLG PRA) at the rate of $15.94 per preferred share, which equates to $0.3984 for each depositary sha

    $FLG
  • Kopin Corporation Receives Two Major Honors at 2026 Massachusetts Manufacturing Mash-Up
    PR·

    Kopin Corporation Receives Two Major Honors at 2026 Massachusetts Manufacturing Mash-Up

    Awarded M2I2 $800K Grant to Advance Domestic AI Infrastructure Manufacturing and Named Manufacturer of the Year by Massachusetts Legislative Manufacturing Caucus Kopin Corporation (NASDAQ:KOPN), a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical products, today announced it has been recognized with two significant honors at the 2026 Massachusetts Manufacturing Mash-Up, where the Massachusetts Center for Advanced Manufacturing (CAM) brings together industry leaders, innovators, and ecosystem partners to celebrate manufacturing achievements. The company has been awarded funding thr

    $KOPN
  • Reborn Coffee Secures Manufacturing Infrastructure for $30 Million Supply Volume and Expands Global Supply Chain via Tri-Party Agreement with Korean Vietnamese OEM Leaders
    PR·

    Reborn Coffee Secures Manufacturing Infrastructure for $30 Million Supply Volume and Expands Global Supply Chain via Tri-Party Agreement with Korean Vietnamese OEM Leaders

    Establishes a strategic tri-party manufacturing framework among Reborn Coffee, Visvita Korea (utilizing Visvita Corp's IP), and top-tier South Korean and Vietnam OEM beverage leaders Secures reliable Korean production infrastructure capable of supporting the $30 million annual supply target, with the initial $2 million purchase order (PO) already confirmed and fulfillment underway

    $REBN
  • Phunware CEO Dmitry Kroshka to Highlight Guest Intelligence Platform at Emerging Growth Conference on October 29 at 9:40 AM ET
    PR·

    Phunware CEO Dmitry Kroshka to Highlight Guest Intelligence Platform at Emerging Growth Conference on October 29 at 9:40 AM ET

    Phunware, Inc. ("Phunware" or the "Company") (NASDAQ:PHUN), a provider of AI-enabled guest intelligence software to operators of hotels, resorts and other large, complex properties, today announced that Chief Executive Officer Dmitry Kroshka will present at Emerging Growth Conference 97 on Thursday, October 29, 2026, at 9:40 a.m. Eastern Time. The virtual presentation will include a question-and-answer session, and investors may request one-on-one meetings with management. Mr. Kroshka will provide an overview of Phunware 2.0 and the Company's Guest Intelligence Platform. The discussion will cover how Phunware is bringing together location i

    $PHUN
  • HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026
    PR·

    HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026

    ALIGN-ACS pilot study compared the HeartBeam 3D ECG technology to a standard 12-lead ECG for detection of acute coronary syndrome (ACS) Results will inform the design of HeartBeam’s planned U.S. pivotal study, building on recent FDA Breakthrough Device Designation for heart attack assessment and acceptance into FDA’s Total Product Life Cycle Advisory Program (TAP) HeartBeam management team will be available to meet with key opinion leaders, industry leaders, media, and analysts during TCT 2026 HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the results of the ALIGN-ACS pil

    $BEAT
  • John Marshall Bancorp, Inc. Reports 3rd Quarter Net Income Increases 39.5% Versus Year Ago Quarter - Funding, Asset Quality, and Capital Position Company for Anticipated Growth
    PR·

    John Marshall Bancorp, Inc. Reports 3rd Quarter Net Income Increases 39.5% Versus Year Ago Quarter - Funding, Asset Quality, and Capital Position Company for Anticipated Growth

    John Marshall Bancorp, Inc. (NASDAQ:JMSB) (the "Company"), parent company of John Marshall Bank (the "Bank"), reported net income of $7.5 million for the quarter ended September 30, 2026, compared to $5.4 million for the quarter ended September 30, 2025, an increase of $2.1 million or 39.5%. Diluted earnings per common share were $0.53 for the quarter ended September 30, 2026, compared to $0.38 for the quarter ended September 30, 2025, also an increase of 39.5%. Annualized return on average assets ("ROAA") was 1.23% for the quarter ended September 30, 2026, compared to 0.94% for the quarter ended September 30, 2025. Annualized return on average equity ("ROAE") was 10.78% for the quarter end

    $JMSB
  • NUBURU Highlights Completed TEKNE Acquisition and Execution Priorities Ahead of NYSE American Equity Compliance Deadline
    PR·

    NUBURU Highlights Completed TEKNE Acquisition and Execution Priorities Ahead of NYSE American Equity Compliance Deadline

    Established Italian manufacturer adds approximately 185 personnel and three facilities as management focuses on customer programs, deliveries and cash generation NUBURU, Inc. (NYSE:BURU) ("NUBURU" or the "Company") today highlighted the completion of its acquisition of a 70% controlling interest in TEKNE S.p.A. ("TEKNE"), its previously reported stockholders’ equity position, and its operating priorities as the Company’s NYSE American equity compliance plan period approaches its October 29, 2026 deadline. The completed TEKNE acquisition advances NUBURU’s transformation into an integrated defense and security technology business. TEKNE brings an established Italian defense manufacturer w

    $BURU
  • Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
    PR·

    Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors

    Vir Biotechnology, Inc. (NASDAQ:VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr. Topalian is the Bloomberg-Kimmel Professor of Cancer Immunotherapy at the Johns Hopkins University School of Medicine* and serves as Associate Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Director Melanoma/Skin Cancer Program in the Kimmel Cancer Center at Johns Hopkins. "Suzanne brings extraordinary depth of expertise in cancer immunotherapy and a track record of advancing groundbreaking science into meaningful solutions for patients," said Marianne De Backer, President and Chief Executive Officer of Vir Bio

    $VIR